ReviewSpringer seminars in immunopathology2006
Combination DNA plus protein HIV vaccines.
Review in Springer seminars in immunopathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.Human gene therapy · 2018Trial
- Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?IJID regions · 2023Article
- Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review.Infectious disease reports · 2022Review
- Revival of the heterologous prime-boost technique in COVID-19: An outlook from the history of outbreaks.Health science reports · 2022Review
- Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine.Frontiers in immunology · 2017Article
- A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Evaluation of Lethal Giant Larvae as a Schistosomiasis Vaccine Candidate.BioMed research international · 2016Article
- HIV vaccine development: an exploratory review of the trials and tribulations.Immunologic research · 2014Review
- Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.Journal of virology · 2014Article
- DNA Immunization for HIV Vaccine Development.Vaccines · 2014Review
- Article
- Protective effect of a prime-boost strategy with the Ts87 vaccine against Trichinella spiralis infection in mice.BioMed research international · 2014Article
- Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice.PloS one · 2013Article
- Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.Vaccine · 2011Article
- Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.Journal of translational medicine · 2010Article
- Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.The Journal of biological chemistry · 2010Article
- Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.Vaccine · 2010Article
- DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.Gene therapy · 2010Article
- Heterologous prime-boost vaccination.Current opinion in immunology · 2009Review
- Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major challenge in developing an HIV vaccine is to identify immunogens and delivery methods that will elicit balanced humoral and cell mediate immunities against primary isolates of HIV with diverse sequence variations. Since the discovery of using protein coding nucleic acids (mainly DNA but also possible RNA) as a means of immunization in the early 1990s, there has been rapid progress in the creative use of this novel approach for the development of HIV vaccines. Although the initial impetus of using DNA immunization was for the induction of strong cell-mediated immunity, recent studies have greatly expanded our understanding on the potential role of DNA immunization to elicit improved quality of antibody responses. This function is particularly important to the development of HIV vaccines due to the inability of almost every previous attempt to develop broadly reactive neutralizing antibodies against primary HIV-1 isolates. Similar to the efforts of developing cell mediated immunity by using a DNA prime plus viral vector boost approach, the best antibody responses with DNA immunization were achieved when a protein boost component was included as part of the immunization schedule. Current experience has suggested that a combination DNA plus protein vaccination strategy is able to utilize the benefits of DNA and protein vaccines to effectively induce both cell-mediated immunity and antibody responses against invading organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.